Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Live Attenuated Varicella Vaccine in Adolescents and Adults
NCT06592456Phase 3Completed
- Sponsor
- Southeast University
- Start
- Jul 2019
- Primary completion
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of varicella vaccine live in chickenpox (2 arms), sponsored by Southeast University. Primary endpoint: Seroconversion Rate at 42 days. Started Jul 2019; status: completed.
02
Drugs
varicella vaccine live
03
Conditions
chickenpox
Beyond the preview
Go deeper on NCT06592456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592456.